We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Ultrasensitive Troponin-I Assay to Be Introduced at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2013
Print article
An advanced rapid assay for the heart attack biomarker troponin-I is being introduced to American cardiac researchers and clinicians at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

Abbot Diagnostics (Abbot Park, IL, USA) will be demonstrating the ARCHITECT High Sensitive Troponin-I (hsTnI) assay at the Clinical Lab Expo. In a study recently completed at Brigham and Women’s Hospital (Boston, MA, USA) this test was compared to a fourth generation troponin T assay among 4,695 patients presenting with severe chest pain.

Results revealed that the ARCHITECT hsTnI assay could detect very low levels of troponin-I, which allowed doctors to evaluate whether or not patients were having a heart attack within two to four hours after presentation. Furthermore, the test was so sensitive that doctors were able to predict which patients presenting with symptoms of a heart attack, such as severe chest pain, were at a higher risk for having a heart attack up to 30 days later.

"This study adds to the clinical evidence confirming the advantages of Abbott’s high sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests," said Dr. John Frels, divisional vice president, diagnostics research at Abbott Diagnostics. "This is important information for patient care because it may help doctors focus on the patients at greater risk for appropriate management."

The ARCHITECT hsTnI assay – already being marketed in Europe – was designed to run on Abbott’s automated ARCHITECT family of analyzers.

Related Links:
Abbot Diagnostics


Gold Supplier
Real-Time PCR System
CFX Opus 384 System
New
High Throughput Electrolyte Analyzer
CBS-50
New
Progesterone ELISA Test
17-Alpha Hydroxy Progesterone ELISA
New
Portable Tube Luminometer
Junior LB 9509

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries (Photo courtesy of Takara Bio)

Cell-free RNA Profiles Gauge Preeclampsia Risk Months Before Symptoms

The period from conception to delivery represents the most rapid growth and development in an individual’s life. The ability to support this development requires dramatic and inadequately understood alterations... Read more

Hematology

view channel
Image: QX200 AutoDG ddPCR System and QXDx BCR-ABL %IS Kit (Photo courtesy of Bio-Rad)

ddPCR Developed for BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia

Droplet digital polymerase chain reaction (ddPCR) is a novel polymerase chain reaction (PCR) technique reliant on massive sample partitioning to generate individual reaction chambers (droplets) in which... Read more

Industry

view channel
Illustration

Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots

The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.